Core Viewpoint - A class action lawsuit has been filed against StubHub Holdings, Inc. on behalf of investors who acquired StubHub securities during the specified Class Period, highlighting potential undisclosed issues related to the company's IPO [1][3]. Group 1: Lawsuit Details - The lawsuit is initiated by Berger Montague PC, representing investors who purchased StubHub securities from September 14, 2025, to November 24, 2025, including shares from the September 2025 IPO [1][2]. - Investors have until January 23, 2026, to seek appointment as lead plaintiff representatives of the class [2]. Group 2: Allegations Against StubHub - The complaint alleges that StubHub's IPO Registration Statement failed to disclose significant changes in the timing of payments to vendors, which adversely affected the company's free cash flow [3].

SAN DIEGO, Jan. 20, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Wealthfront Corporation (NASDAQ: WLTH). If you have information that could assist in the Wealthfront investigation or if you are a Wealthfront investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-wealthfront-corporation-investigation-wlth.html Past results do not gua ...

Core Viewpoint - Kaskela Law LLC is investigating Select Medical Holdings Corporation to determine potential violations of securities laws or breaches of fiduciary duties by the company and its officers and directors in relation to recent corporate actions [1]. Group 1 - The investigation is initiated on behalf of Select Medical shareholders [1]. - Shareholders are encouraged to contact Kaskela Law LLC for more information regarding their legal rights and options [2]. - Kaskela Law LLC specializes in representing investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis [2].

Core Viewpoint - A class action lawsuit has been filed against Bath & Body Works, Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Ohio, captioned Lingam v. Bath & Body Works, Inc., et al., No. 2:26-cv-00039 [3]. - Investors have until March 16, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Strategy - Bath & Body Works is a specialty retailer focusing on home fragrance and body care products, exploring product categories beyond its core business, including men's products, lip care, hair care, and laundry items [4]. - The company claimed that customers were responding favorably to its innovations and that its strategy was effective in driving topline growth [5]. Group 3: Stock Performance and Financial Results - On August 28, 2025, Bath & Body Works reported disappointing Q2 2025 results, cutting its full-year earnings guidance by $0.03 to a range of $3.28 to $3.53, leading to a stock price drop of $2.18 per share, or 6.9% [6]. - Following the Q3 2025 results on November 20, 2025, which included a further reduction in full-year guidance and acknowledgment that the strategy had not grown the customer base, the stock fell by $5.22 per share, or 24.8% [7].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Alexandria Real Estate is a real estate investment trust (REIT) focused on tenants in life science industries, including pharmaceutical and biotechnology companies [4]. Financial Performance - Alexandria Real Estate reported lower-than-expected results for Q3 2025, leading to a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 between October 27 and October 28, 2025 [6]. - The company announced a real estate impairment charge of $323.9 million, with $206 million attributed to its Long Island City property, which was deemed not suitable for life science scaling [5][6]. Legal Proceedings - Investors have until January 26, 2026, to request to lead the class action case, which is pending in the U.S. District Court for the Central District of California [3]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Alexandria Real Estate securities [3].

Core Viewpoint - A class action lawsuit has been filed against Integer Holdings Corporation and its senior executives for securities fraud following a significant drop in stock price due to alleged violations of federal securities laws [1]. Company Overview - Integer Holdings Corporation specializes in designing and manufacturing cardiac rhythm management and cardiovascular products, including electrophysiology devices that diagnose and treat arrhythmias [4]. Allegations of Securities Fraud - The lawsuit claims that Integer misrepresented the demand and revenue for its electrophysiology products, which had reportedly fallen sharply, contradicting the company's public statements about sales growth and market position [5][4]. Stock Price Decline - On October 23, 2025, Integer revised its 2025 sales guidance down to between $1.840 billion and $1.854 billion, below analysts' expectations, and projected poor net sales growth of -2% to 2% for 2026. This announcement led to a stock price drop of $35.22 per share, over 32%, from $109.11 to $73.89 [6].

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that it has filed a class action lawsuit against Ardent Health, Inc. (NYSE:ARDT) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from potential violations of the federal securities laws. If you invested in Ardent Health, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ardent-health-inc-class-act ...

Core Viewpoint - The SLM Corporation, also known as Sallie Mae, is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims of misleading statements regarding the company's loan delinquency rates and loss mitigation programs [1][3]. Group 1: Class Action Details - Investors in SLM securities from July 25, 2025, to August 14, 2025, can seek appointment as lead plaintiff by February 17, 2026 [1]. - The lawsuit is titled Zappia v. SLM Corporation and is filed in the District of New Jersey [1]. - The allegations include that SLM experienced a significant increase in early-stage delinquencies, contradicting previous statements made by the company's executives [3][4]. Group 2: Financial Impact - A report from investment bank TD Cowen indicated that July 2025 delinquencies increased by 49 basis points month-over-month, which was worse than the seasonal average increase of 10 basis points [4]. - Following the release of this report, SLM's stock price fell by approximately 8% [4]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who suffered losses during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [5]. - The lead plaintiff can choose a law firm to represent the class, and participation as lead plaintiff does not affect the ability to share in any potential recovery [5]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [6]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [6].

Core Viewpoint - A class action lawsuit has been filed against Endeavor Group Holdings, Inc. and certain affiliated parties for alleged violations of federal securities laws during the Class Period from January 15, 2025, to March 24, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Endeavor Class A common stock during the specified Class Period [2]. - The Complaint alleges that Defendants made materially false and misleading statements regarding the fairness of a take-private merger and the $27.50-per-share Merger Consideration [3]. - It is claimed that Defendants orchestrated a scheme to disadvantage minority shareholders while insiders benefited from rollovers and other advantages [3][6]. Group 2: Allegations Against Defendants - Defendants are accused of structuring the merger to disadvantage minority shareholders by rejecting a "majority-of-the-minority" vote and closing the transaction through controller written consent [6]. - The merger included a fixed cash-out consideration of $27.50 without any collar or contingent value rights, and insiders received a minimal dividend [6]. - A misleading Information Statement was disseminated on January 15, 2025, which misrepresented the fairness and best interests of unaffiliated shareholders, relying on outdated fairness opinions [6]. Group 3: Next Steps for Investors - Investors who suffered losses in Endeavor have until March 18, 2026, to request to be appointed as lead plaintiff in the case [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only recover costs if successful [5].

Core Viewpoint - Jayud Global Logistics Limited is facing a securities fraud class action lawsuit due to allegations of misleading statements and involvement in a "pump-and-dump" scheme during its trading period from April 21, 2023, to April 30, 2025 [1][5]. Group 1: Company Overview - Jayud went public through an initial public offering (IPO) in April 2023, offering only 1.25 million shares, which is less than 5% of its total outstanding equity, while maintaining significant insider control [2]. - The stock price of Jayud surged from approximately $1.00 to an all-time high of $7.97 per share by April 1, 2025, resulting in a market capitalization of around $720 million, despite the absence of any fundamental news [3]. Group 2: Allegations and Lawsuit Details - The lawsuit alleges that during the Class Period, the defendants made materially false and misleading statements and failed to disclose adverse facts about the company's operations and prospects [5]. - Specific allegations include the failure to disclose that Jayud was involved in a fraudulent stock promotion scheme, the use of offshore accounts for coordinated share dumping, and the omission of information regarding false rumors and artificial trading activity that inflated the stock price [5]. Group 3: Legal Proceedings - Investors who acquired Jayud securities between April 21, 2023, and April 30, 2025, have until January 20, 2026, to seek appointment as lead plaintiff in the class action lawsuit [1][6].